Clinical Trials
50 trialsA Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Zai Lab (Hong Kong), Ltd.
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
Novartis
CYCLIGIST
Institut Bergonié
A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
Zai Lab (Hong Kong), Ltd.
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Cogent Biosciences, Inc.
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stanford University
Study for Patients Previously Treated in Avapritinib Clinical Trials
Blueprint Medicines Corporation
EDO-S101
Mundipharma Research Limited
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Novartis
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Novartis
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
Pfizer
INVICTUS
Deciphera Pharmaceuticals, LLC
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
Ludwig Institute for Cancer Research
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Blueprint Medicines Corporation
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
SURE
Dana-Farber Cancer Institute
GRID
Bayer
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Dana-Farber Cancer Institute
Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258
Asan Medical Center
Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
Asan Medical Center
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
Asan Medical Center
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Pfizer
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Pfizer
Trial of Dasatinib in Advanced Sarcomas
Sarcoma Alliance for Research through Collaboration
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
National Cancer Institute (NCI)
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
GIST
Takeda
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Novartis
MUCIN
Northwestern University
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
National Cancer Institute (NCI)
SIGNATURE
Novartis
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
Pfizer
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
Novartis
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
SCRI Development Innovations, LLC
ENESTg1
Novartis
Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
Novartis
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
Synta Pharmaceuticals Corp.
GIST
Pfizer
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
Novartis
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
AstraZeneca
ENEST
Novartis
Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo
Cirujanos la Serena
A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)
Pfizer
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
Pfizer
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
Pfizer